Venatorx’s Cefepime-Taniborbactam Shows Positive Results in Phase 3 Study
Ventatorx Pharmaceuticals’ investigational antibiotic cefepime-taniborbactam has shown promise in a late-stage study for treatment of complicated urinary tract infections.
The drug candidate was compared with the antibiotic meropenem and was found to be superior in some respects. The drug was more effective than meropenem against several pathogens, including cefepime-resistant, extended-spectrum beta-lactamase-producing and multidrug-resistant bacteria.
The company said it plans to submit a New Drug Application for the antibiotic to the FDA in the first half of next year.
Venatorx is presenting the data at IDWeek in Washington, D.C., Oct. 19-23.